2025-04-04 - Analysis Report
## UnitedHealth Group Inc. (UNH) Stock Analysis Report

**0. Executive Summary:**

UnitedHealth Group Inc. (UNH), a diversified healthcare company, has significantly outperformed the S&P 500 (VOO) over the given period.  While showing strong revenue and profitability, recent price action suggests potential overvaluation, warranting cautious optimism.

**1. Performance Comparison & Alpha/Beta Analysis:**

UNH's cumulative return (119.04%) significantly exceeds the S&P 500's return (85.44%), resulting in a substantial outperformance of 33.6 percentage points.  The relative divergence of 37.1% (within the historical range of -9.3% to 106.2%) indicates UNH's superior performance compared to the benchmark.  However, this superior performance needs to be considered in context of market risk.

The Alpha/Beta analysis reveals varying performance across different periods.  While high CAGR is observed in many periods (exceeding 50% in several instances), high Maximum Drawdowns (MDD) point to significant risk.  The fluctuating Alpha suggests periods of both outperformance and underperformance relative to the market, with a generally positive alpha suggesting outperformance overall. The Beta consistently stays around 0.2-0.3, indicating a moderate sensitivity to market fluctuations.  Market capitalization grew substantially during the observed period.

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 62.0% | 5.8% | 44.0% | 0.0 | 181.0 |
| 2016-2018  | 53.0% | 50.8% | 47.0% | 0.2 | 207.3 |
| 2017-2019  | 40.0% | 50.8% | 21.0% | 0.1 | 248.8 |
| 2018-2020  | 12.0% | 50.8% | -22.0% | 0.2 | 301.7 |
| 2019-2021  | 74.0% | 24.0% | 1.0% | 0.2 | 438.0 |
| 2020-2022  | 80.0% | 49.7% | 69.0% | 0.3 | 468.4 |
| 2021-2023  | 56.0% | 49.7% | 38.0% | 0.3 | 472.1 |
| 2022-2024  | -16.0% | 49.7% | -39.0% | 0.3 | 460.8 |
| 2023-2025  | -1.0% | 55.9% | -38.0% | 0.1 | 494.4 |


**2. Recent Price Action:**

The stock closed at $540.44, a significant increase of $3.3 from the previous close ($523.2).  This indicates a recent surge.  The short-term trends show the price above all moving averages:

* **5-day MA:** $525.31
* **20-day MA:** $506.67
* **60-day MA:** $510.63

This suggests a strong upward momentum in the short term.  However, this rapid price increase necessitates caution regarding potential short-term correction.

**3. Technical Indicators & Expected Return:**

* **Market Risk Indicator (MRI):** 0.432 (Medium Risk) suggests a moderate level of market risk.
* **RSI:** 89.21, extremely overbought, implying a high probability of a near-term correction or pullback.
* **PPO:** 0.74, indicating a strong bullish momentum.
* **Delta_Previous_Relative_Divergence:** +12.8, reinforces the short-term upward trend.
* **Expected Return:** 91.8% –  A very high projected excess return over the S&P 500 over the long term (2+ years).  However, this forecast requires careful consideration given the already high valuation indicated by the RSI and the recent price surge.  This high projected return needs to be evaluated against the risk profile suggested by other indicators.


**4. Recent Earnings Analysis:**

The earnings data reveals some volatility. While revenue is consistently high and increasing, EPS shows significant fluctuation, including a negative EPS in one quarter.  Further investigation into the reasons for these fluctuations would be beneficial.

| 날짜       | EPS    | 매출          |
|------------|--------|----------------|
| 2024-11-04 | 6.56   | 100.82 B$      |
| 2024-08-09 | 4.58   | 98.86 B$      |
| 2024-05-09 | -1.53  | 99.80 B$      |
| 2023-11-06 | 6.31   | 92.36 B$      |
| 2024-11-04 | 6.31   | 92.36 B$      | *(Duplicate Data)*


**5. Financial Information:**

Both revenue and profit margins show relatively stable and strong performance.  However, the Equity and ROE data indicate some variability, with a negative ROE in one quarter. Further analysis is required to understand these fluctuations.

**Revenue and Profitability:**

| Quarter | Revenue      | Profit Margin |
|---------|--------------|---------------|
| 2024-12-31 | $100.81B     | 21.14%        |
| 2024-09-30 | $100.82B     | 22.84%        |
| 2024-06-30 | $98.86B      | 22.31%        |
| 2024-03-31 | $99.80B      | 23.05%        |
| 2023-12-31 | $94.43B      | 23.30%        |


**Capital and Profitability:**

| Quarter | Equity       | ROE     |
|---------|--------------|---------|
| 2024-12-31 | $92.66B      | 5.98%   |
| 2024-09-30 | $94.53B      | 6.41%   |
| 2024-06-30 | $89.36B      | 4.72%   |
| 2024-03-31 | $86.69B      | -1.63%  |
| 2023-12-31 | $88.76B      | 6.15%   |


**6. Overall Analysis:**

UNH has demonstrated significant outperformance compared to the S&P 500,  supported by strong revenue and profitability.  However, the recent price surge, coupled with an extremely overbought RSI and the volatility observed in EPS and ROE, raises concerns about potential short-term corrections. While the long-term outlook is positive, based on the high projected excess return, caution is advised given the current high valuation and risk of a short-term pullback.  A more in-depth analysis of the reasons behind the EPS and ROE fluctuations, as well as a consideration of potential market headwinds, is recommended before making any investment decisions.  Further investigation into the duplicate data point in the earnings analysis is also required.
